ID

13060

Beschreibung

Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00083577

Link

https://clinicaltrials.gov/show/NCT00083577

Stichworte

  1. 13.01.16 13.01.16 -
Rechteinhaber

CC BY-NC 3.0

Hochgeladen am

13. Januar 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Multiple Myeloma NCT00083577

Eligibility Multiple Myeloma NCT00083577

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
all patients must have a confirmed diagnosis of previously treated, active multiple myeloma
Beschreibung

multiple myeloma

Datentyp

boolean

Alias
UMLS CUI [1]
C0026764
myeloma protein should be evident from which to evaluate response
Beschreibung

myeloma protein

Datentyp

boolean

Alias
UMLS CUI [1]
C0027015
must be 18 years of age or older. women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
Beschreibung

age, contraception

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0700589
patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
Beschreibung

informed consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
patients must have a total white blood cell count of 2,000 k/microliters. patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
Beschreibung

white blood cell count

Datentyp

boolean

Alias
UMLS CUI [1]
C0023508
patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dl.
Beschreibung

liver function

Datentyp

boolean

Alias
UMLS CUI [1]
C1278039
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients must not have an active infection requiring parenteral antibiotics
Beschreibung

active infection

Datentyp

boolean

Alias
UMLS CUI [1]
C0009450
no other concurrent therapy for myeloma is permitted while on thalidomide
Beschreibung

concurrent therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0039736

Ähnliche Modelle

Eligibility Multiple Myeloma NCT00083577

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
multiple myeloma
Item
all patients must have a confirmed diagnosis of previously treated, active multiple myeloma
boolean
C0026764 (UMLS CUI [1])
myeloma protein
Item
myeloma protein should be evident from which to evaluate response
boolean
C0027015 (UMLS CUI [1])
age, contraception
Item
must be 18 years of age or older. women of childbearing age and fertile men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
boolean
C0001779 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
informed consent
Item
patients must sign an informed consent to participate in this study, and be fully aware of the known teratogenic potential of this drug
boolean
C0021430 (UMLS CUI [1])
white blood cell count
Item
patients must have a total white blood cell count of 2,000 k/microliters. patients may be anemic or thrombocytopenic provided this is felt to be due to extensive marrow involvement with myeloma
boolean
C0023508 (UMLS CUI [1])
liver function
Item
patients must have adequate liver function as demonstrated by a direct bilirubin of < or = 2.0 mg/dl.
boolean
C1278039 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
active infection
Item
patients must not have an active infection requiring parenteral antibiotics
boolean
C0009450 (UMLS CUI [1])
concurrent therapy
Item
no other concurrent therapy for myeloma is permitted while on thalidomide
boolean
C0039736 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video